Effect of evolocumab versus placebo added to standard lipid-lowering therapy on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia
Event:
ESC Congress 2022
Topic:
Drug therapy
Session:
Optimal risk factor therapy in high risk patients
Remnant cholesterol increases the risk for recurrent vascular events independent of ldl-cholesterol in patients with clinical manifest vascular disease.
Event:
ESC Congress 2019
Topic:
Lipids
Session:
Lipids / Cardiovascular risk prediction / Life style
